|
市場調査レポート
商品コード
1309676
骨補填材の世界市場規模、シェア、産業動向分析レポート:タイプ別、形態別、用途別、エンドユーザー別、地域別展望・予測、2023年~2030年Global Bone Void Fillers Market Size, Share & Industry Trends Analysis Report By Type, By Form (Gel & Putty, Granules and Others), By Application (Bone Fracture, Spine Fusion and Others), By End User, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
骨補填材の世界市場規模、シェア、産業動向分析レポート:タイプ別、形態別、用途別、エンドユーザー別、地域別展望・予測、2023年~2030年 |
出版日: 2023年06月30日
発行: KBV Research
ページ情報: 英文 256 Pages
納期: 即納可能
![]() |
骨補填材市場規模は2030年までに61億米ドルに達し、予測期間中にCAGR 7.9%の市場成長率で上昇すると予測されています。
手術後の骨感染などの臨床上の制約から、抗生物質溶出性空隙充填材の使用に対する関心が高まっています。市場参入企業は、研究開発努力を加速し、治療中の骨感染も減少させた抗生物質溶出性空隙充填材の提供に注力しています。抗生物質溶出性骨空隙充填材のイントロダクションは、整形外科手術におけるより良い感染制御方法に対する需要の拡大を反映しています。このような最先端製品の発売は、予測期間中の市場拡大を促進すると予測されています。合成骨空隙充填材(BVF)は、従来の骨移植材に比べていくつかの利点があるため、近年使用量が増加しています。患者自身の体から採取される自家骨移植片や同種骨移植片の代わりに、合成骨空隙充填材(BVF)は一から作られる材料です。この市場は、硫酸カルシウムやリン酸三カルシウムなどの人工骨空隙充填材の使用増加により発展すると予測されています。2020年の収益は2019年に比べて大幅に減少しました。しかし、2021年には、整形外科・外傷外科を含む選択的手術が再開され始めました。厳しい要件、公共の場でのCOVID-19規範の実施、渡航制限の解除など、いくつかの事情により、患者数と手術件数は回復しました。その結果、2021年にはこれらの製品に対する需要が増加しました。市場の成長見通しは安定していると予想されます。
しかし、さまざまな臨床上の制約や骨空隙充填物質の浸透が不十分なため、需要は減少しています。軟組織や骨への感染、不十分あるいは存在しない骨成長、充填剤の破裂など、その使用に関連する主な危険性や有害性が、この受け入れ減少の原因となっています。臨床医は、質の高い臨床試験の欠如や長期的データの欠如のために、これらのフィラーを利用する最良の方法やその性能について確信が持てないことがあります。したがって、こうした限界が市場の成長力を制限しています。
タイプの展望
タイプ別に見ると、市場は脱灰骨マトリックス、リン酸カルシウム骨移植代替物、コラーゲンマトリックス、その他に区分されます。リン酸カルシウム骨移植代替物セグメントは、2022年の市場でかなりの収益シェアを獲得しました。骨空隙充填材は、骨移植片の代替としてリン酸カルシウムを頻繁に使用します。骨空隙充填材を使用することで、骨嚢胞、骨折、病気や外傷による骨欠損など、骨のあらゆる隙間や欠損を埋めることができます。リン酸カルシウムは生体適合性と骨伝導性に優れているため、このような目的で頻繁に使用されています。
形態の展望
市場は形態によって、ゲル・パテ、顆粒、その他に区分されます。2022年には、ゲル&パテセグメントが市場で最大の収益シェアを占めました。このセグメントの著しい成長は、最近行われている非侵襲的で低侵襲な手術が増えた結果であると考えられます。ハイドロキシアパタイト(HA)やリン酸三カルシウム(TCP)のようなリン酸カルシウムベースの物質は、骨伝導性を高め、骨の再生を助けるが、ゲル&パテベースの骨補填材の両方に含まれています。
用途別展望
用途別に見ると、市場は脊椎固定、骨折、その他に二分されます。2022年には、脊椎融合が市場でかなりのセグメント収益シェアを占めました。脊椎骨(椎骨)の融合を促し、強固で安定した脊柱を形成するために、骨補填材は脊椎固定手術に不可欠な要素です。脊椎固定術では、骨空隙充填材の選択は、特定の手術方法、骨空隙の位置と大きさ、患者の健康状態、外科医の個人的な好みなど、いくつかの変数に影響されます。治療の特殊なニーズと充填材の望ましい品質に基づき、顆粒、パテ、ゲルベースの充填材など、他のタイプの骨移植代替材が採用されることもあります。
エンドユーザーの展望
エンドユーザー別では、市場は病院、専門クリニック、その他に細分化されます。2022年には、病院セグメントが最大の売上シェアで市場を独占しました。先進国と発展途上国の両方における病院の拡大が成長の原因となっています。さらに、予想される期間中、治療を受けるために病院に相談する患者が多く、病院施設で実施される整形外科治療の数が増加することも、同分野の拡大を後押しすると予測されます。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米地域が最も高い収益シェアを獲得して市場をリードしました。これは、人工骨空隙充填材の使用の増加、大規模な骨空隙充填材ビジネス、洗練されたヘルスケアシステムの存在、骨空隙充填材の普及に起因します。
List of Figures
The Global Bone Void Fillers Market size is expected to reach $6.1 billion by 2030, rising at a market growth of 7.9% CAGR during the forecast period.
The main factor contributing to the rise of bone fracture, particularly in children, is a particular sport's year-round participation. Bone fracture is expected to acquire more than 53% share of the market by 2030. About 30 million children and teenagers in the United States take part in organized sports of some kind, and each year, these athletes suffer more than 3.5 million injuries that limit their ability to play for a period of time. Sports-related injuries account for nearly one-third of all injuries sustained by children. Sprains and strains are the most typical types of injuries. Undoubtedly, some sports are riskier than others. For instance, it is logical to anticipate that contact sports like football will cause more injuries than noncontact activities like swimming.
Sports-related injuries affect more than 775,000 kids aged 14 and under, who receive annual treatment in hospital emergency rooms. Sports-related injuries are therefore growing more frequent, especially in young people, which is expected to increase demand for bone void fillers. Some of the factors impacting the market are growing attention toward launching antibiotic eluting bone void fillers, rising acceptance of synthetic BVF, and lesser availability and clinical barriers.
Clinical restrictions, like bone infection after surgery, have heightened interest in using antibiotic-eluting void fillers. The market participants are focusing on accelerating R&D efforts and offering antibiotic-eluting void fillers that have also decreased bone infection while undergoing therapy. The introduction of antibiotic-eluting bone void fillers reflects the expanding demand for better infection control methods in orthopedic procedures. The launch of such cutting-edge products is projected to drive the market's expansion over the forecast period. Because they provide several advantages over conventional bone graft materials, synthetic bone void fillers (BVF) have increased usage in recent years. In place of autografts or allografts-which are taken from the patient's own body-synthetic BVFs are made-from-scratch materials. The market is predicted to develop due to the rising use of artificial bone void fillers such as calcium sulfate and tricalcium phosphate. The revenue generated was significantly lower in 2020 than it was in 2019. However, in 2021, elective procedures-including orthopedic & trauma surgery-began to resume as the government-imposed restrictions in various countries were removed. Due to several circumstances, including stringent requirements, implementing COVID-19 norms in public settings, and lifting travel restrictions, the number of patients and surgeries recovered. As a result, there was more demand for these products in 2021. Market growth prospects are anticipated to be consistent.
However, demand is declining due to various clinical limitations and inadequate bone void filling substance penetration. The major dangers and hazards associated with its usage, such as infection of soft tissue & bone, insufficient or non-existent bone growth, filler rupture, etc., cause this declining acceptance. Clinicians may be unsure of the best way to utilize and how these fillers will perform due to a lack of high-quality trials or a lack of long-term data. Therefore, these limitations are limiting the market's ability to grow.
Type Outlook
Based on type, the market is segmented into demineralized bone matrix, calcium phosphate bone graft substitute, collagen matrix, and others. The calcium phosphate bone graft substitute segment acquired a substantial revenue share in the market in 2022. Bone void fillers frequently use calcium phosphate as a replacement for bone grafts. Using a bone void filler can fill in any gaps or defects in a bone, including those caused by bone cysts, fractures, or disease- or trauma-induced bone loss. Because of their biocompatibility and osteoconductive qualities, replacements made of calcium phosphate are frequently used for this purpose.
Form Outlook
On the basis of form, the market is segmented into gel & putty, granules, and others. In 2022, the gel & putty segment witnessed the largest revenue share in the market. The segment's significant growth can be the result of the more non-invasive and minimally invasive operations being performed these days. Calcium phosphate-based substances, like hydroxyapatite (HA) or tricalcium phosphate (TCP) that enhance osteoconductivity and assist bone regeneration can be present in both gel & putty-based bone void fillers.
Application Outlook
On the basis of application, the market is bifurcated into spine fusion, bone fracture and others. In 2022, the spine fusion covered a considerable segment revenue share in the market. To encourage the fusing of the spinal bones (vertebrae) and produce a solid and stable spinal column, bone void fillers are an essential component of spinal fusion surgeries. In a spine fusion, the choice of bone void fillers is influenced by several variables, including the specific surgical approach, the location & size of the bone void, the patient's health, and the surgeon's personal preferences. Based on the treatment's particular needs and the filler material's desired qualities, other types of bone graft substitutes, such as granules, putty, or gel-based fillers, may be employed.
End User Outlook
By end user, the market is fragmented into hospital, specialty clinics, and others. In 2022, the hospital segment dominated the market with the maximum revenue share. The expansion of hospitals in both developed and developing nations is blamed for the growth. In addition, it is anticipated that during the anticipated timeframe, a sizable patient pool consulting hospitals to receive treatment and an increase in the number of orthopedic treatments performed in hospital facilities will support segmental expansion.
Regional Outlook
Region wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is attributable to the increased use of artificial bone void fillers, a sizable bone void filler business, the presence of a sophisticated healthcare system, and the widespread availability of bone void fillers.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, DePuy Synthes (Johnson & Johnson), Orthofix Medical, Inc., Stryker Corporation, Zimmer Biomet Holdings, Inc., Smith & Nephew PLC, NuVasive, Inc., Baxter International, Inc., Biocomposites Ltd., and Arthrex, Inc.
Strategies Deployed in Bone Void Fillers Market
Feb-2023: NuVasive got an FDA 510(k) approval Modulus Cervical interbody implant to be used with a bone void filler. The approval shows a notable milestone towards the aim to broaden companies advanced materials integration of Modulus and Attrax Putty to its cervical interbody into the C360 offerings.
Mar-2022: Orthofix came into partnership with MTF Biologics, a global nonprofit organization. Following this partnership, MTF Biologics would be the sole provider of the MTF allograft portfolio. The addition of the Legacy demineralized bone line would broaden its biologic suite, enhancing the options available and providing a valuable solution for its customers and patients.
Feb-2022: Orthofix Medical announced the launch of The Opus BA solution, a bioactive bone graft for spine procedures. The product would be utilized to fill bone voids or gaps in the skeletal system for lumbar and cervical spine fusion procedures.
Feb-2022: Johnson & Johnson's DePuy Synthes acquired CrossRoads Extremity Systems, a provider of foot and ankle implant systems. Through this acquisition, DePuy Synthes aims to propel its podiatric, orthopaedic, and MedTech advancements from both external and internal innovation.
Jan-2022: NuVasive, Inc. received FDA approval for expanded indications of usage for Attrax Putty with its complete thoracolumbar interbody offerings for spine surgery. The Attrax Putty is a synthetic, osteoconductive, and bioactive bone void filler developed to lead bone fusion. The approval would advance the standard of spine care - while offering better economic value to NuVasive's customers.
Sep-2021: Orthofix Medical Inc. introduced the Opus Mg Set osteoconductive scaffold, a synthetic magnesium-based bone void filler for orthopaedic procedures. The launched product offers a procedure-specific solution for orthopaedic fracture care and trauma applications by filling non-structural bony voids or gaps at the time of surgery.
Jul-2021: Arthrex partnered with Celularity Inc., a clinical-stage biotechnology company engaged in the development of biomaterial and cell therapies products. Under this partnership, both companies would aim to distribute and market Cellularity's biomaterial products for sports medicine and orthopaedic surgery.
Mar-2020: Biocomposites launched STIMULAN® Rapid Cure 3cc, an addition to the company's US product suite targeting smaller voids in the foot and ankle, orthopaedic reconstruction, and trauma. The launch would be developed particularly for smaller voids in the foot and ankle, orthopaedic reconstruction, and trauma procedures.
Jun-2019: Medtronic acquired Titan Spine, a titanium spine interbody implant and surface technology company. This acquisition strengthens Medtronic's position as a leading company in procedural solutions for spine surgery.
Apr-2019: Smith & Nephew plc took over Osiris Therapeutics, Inc., a stem cell company engaged in developing and commercializing regenerative medicine products consisting of skin, bone graft, and articular cartilage substitutes. This acquisition would boost the growth of Smith & Nephew's Advanced Wound Management franchise.
Apr-2019: Stryker Corporation completed the acquisition of Wright Medical, a global device company that specializes in extremities. Under this acquisition, Stryker would combine the complementary strengths and collective resources and advance its wide platform of extremities and biologics technologies.
Feb-2019: Medtronic plc introduced Grafton Demineralized Bone Matrix (DBM) bone grafting product for spine and orthopaedic procedures, across Japan. The Grafton DBM is a bone graft substitute, bone void filler, and bone graft extender in bony voids or gaps of the skeletal system.
Market Segments covered in the Report:
By Type
By Form
By Application
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research